Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma.

Li R, Gao K, Luo H, Wang X, Shi Y, Dong Q, Luan W, You Y.

J Exp Clin Cancer Res. 2014 Jan 19;33:9. doi: 10.1186/1756-9966-33-9.

2.

An integrated mRNA and microRNA expression signature for glioblastoma multiforme prognosis.

Xiong J, Bing Z, Su Y, Deng D, Peng X.

PLoS One. 2014 May 28;9(5):e98419. doi: 10.1371/journal.pone.0098419. eCollection 2014.

3.

Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.

Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y.

J Transl Med. 2013 Jan 9;11:10. doi: 10.1186/1479-5876-11-10.

4.

Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme.

Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, Kang C, Jiang C, You Y, Zhang Y, Chen CC, Song SW, Jiang T.

Cancer. 2013 Feb 15;119(4):814-24. doi: 10.1002/cncr.27826. Epub 2012 Sep 18.

5.

Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma.

Ma X, Yoshimoto K, Guan Y, Hata N, Mizoguchi M, Sagata N, Murata H, Kuga D, Amano T, Nakamizo A, Sasaki T.

Neuro Oncol. 2012 Sep;14(9):1153-62. doi: 10.1093/neuonc/nos145. Epub 2012 Jul 27.

6.

Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.

Schubert M, Spahn M, Kneitz S, Scholz CJ, Joniau S, Stroebel P, Riedmiller H, Kneitz B.

PLoS One. 2013 Jun 14;8(6):e65064. doi: 10.1371/journal.pone.0065064. Print 2013.

7.

MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients.

Lakomy R, Sana J, Hankeova S, Fadrus P, Kren L, Lzicarova E, Svoboda M, Dolezelova H, Smrcka M, Vyzula R, Michalek J, Hajduch M, Slaby O.

Cancer Sci. 2011 Dec;102(12):2186-90. doi: 10.1111/j.1349-7006.2011.02092.x. Epub 2011 Oct 12.

8.

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type.

Wang Z, Bao Z, Yan W, You G, Wang Y, Li X, Zhang W.

J Exp Clin Cancer Res. 2013 Aug 29;32:59. doi: 10.1186/1756-9966-32-59.

9.

Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, Westhead D, Alder JE, Shaw L, Short SC, Lawler SE.

Mol Oncol. 2015 Mar;9(3):704-14. doi: 10.1016/j.molonc.2014.11.004. Epub 2014 Nov 28.

10.

Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.

Sathyan P, Zinn PO, Marisetty AL, Liu B, Kamal MM, Singh SK, Bady P, Lu L, Wani KM, Veo BL, Gumin J, Kassem DH, Robinson F, Weng C, Baladandayuthapani V, Suki D, Colman H, Bhat KP, Sulman EP, Aldape K, Colen RR, Verhaak RG, Lu Z, Fuller GN, Huang S, Lang FF, Sawaya R, Hegi M, Majumder S.

J Neurosci. 2015 Nov 11;35(45):15097-112. doi: 10.1523/JNEUROSCI.1265-15.2015.

PMID:
26558781
11.

Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis.

Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J.

Lancet Oncol. 2012 Jun;13(6):633-41. doi: 10.1016/S1470-2045(12)70102-X. Epub 2012 May 3.

PMID:
22560814
12.

Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis.

Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, Aldape K, Yung WK.

Neuro Oncol. 2013 Jul;15(7):829-39. doi: 10.1093/neuonc/not024. Epub 2013 Mar 15.

13.

MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis.

Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, Bao Z, Zhang W, You Y, Jiang T.

Oncotarget. 2014 Dec 30;5(24):12908-15.

14.

Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.

Zhang JX, Zhang J, Yan W, Wang YY, Han L, Yue X, Liu N, You YP, Jiang T, Pu PY, Kang CS.

Neuro Oncol. 2013 Mar;15(3):279-89. doi: 10.1093/neuonc/nos306. Epub 2013 Jan 7.

15.

A ten-microRNA expression signature predicts survival in glioblastoma.

Srinivasan S, Patric IR, Somasundaram K.

PLoS One. 2011 Mar 31;6(3):e17438. doi: 10.1371/journal.pone.0017438.

16.

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reyniès A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Fléjou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V.

PLoS Med. 2013;10(5):e1001453. doi: 10.1371/journal.pmed.1001453. Epub 2013 May 21.

17.

MicroRNA expression signatures and their correlation with clinicopathological features in glioblastoma multiforme.

Henriksen M, Johnsen KB, Olesen P, Pilgaard L, Duroux M.

Neuromolecular Med. 2014 Sep;16(3):565-77. doi: 10.1007/s12017-014-8309-7. Epub 2014 May 10.

PMID:
24817689
18.

Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme.

Bao ZS, Zhang CB, Wang HJ, Yan W, Liu YW, Li MY, Zhang W.

CNS Neurosci Ther. 2013 Sep;19(9):714-20. doi: 10.1111/cns.12118. Epub 2013 May 11.

PMID:
23663361
19.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
20.

A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group.

Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, Shailaja BC, Samuel C, Patric IR, Shukla S, Thota B, Prasanna KV, Pandey P, Balasubramaniam A, Santosh V, Chandramouli BA, Hegde AS, Kondaiah P, Sathyanarayana Rao MR.

PLoS One. 2013 Apr 30;8(4):e62042. doi: 10.1371/journal.pone.0062042. Print 2013.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk